The combination of these compounds leads to rapid activation of NFκB signalling and a subsequent induction of a negative feedback loop, mediated via NFκB regulators such as BIRC3, resulting in myeloma cell death. The gene discussed is NFKB1; the disease is plasma cell myeloma.